Serum sex steroids as prognostic biomarkers in patients receiving androgen deprivation therapy for recurrent prostate cancer: a post-hoc analysis of the PR.7 trial

Serum sex steroids as prognostic biomarkers in patients receiving androgen deprivation therapy for recurrent prostate cancer: a post-hoc analysis of the PR.7 trial

Phenotypic biomarkers are a high priority for patients receiving androgen deprivation therapy (ADT) for prostate cancer given the increasing number of treatment options. This study evaluates serum sex steroids as prognostic biomarkers in men receiving ADT for recurrent prostate cancer. Retrospective...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical cancer research 2018-11, Vol.24 (21), p.5305-5312
Hauptverfasser: Toren, Paul, Hoffman, Azik, Ding, Keyue, Joncas, France-Hélène, Turcotte, Veronique, Caron, Patrick, Pouliot, Frédéric, Fradet, Yves, Levesque, Eric, Guillemette, Chantal, Klotz, Laurence H
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Phenotypic biomarkers are a high priority for patients receiving androgen deprivation therapy (ADT) for prostate cancer given the increasing number of treatment options. This study evaluates serum sex steroids as prognostic biomarkers in men receiving ADT for recurrent prostate cancer. Retrospective cohort study of Canadian patients in the PR.7 trial (accrual 1999-2005) who received continuous ADT for biochemical recurrence post-radiotherapy. Patients were excluded with follow-up
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-18-1187